REPT BATTERO (00666) is expected to see a mid-term revenue growth of approximately 22.4% to 29%, with a net loss reduction of about 84.8% to 92.4%.
Ruipu Lanjun (00666) announced that it is expected to achieve revenue by the end of six months ending on June 30, 2025...
REPT BATTERO (00666) announced that, for the six-month period ending on June 30, 2025, the Group expects to achieve revenue of approximately RMB 9.3 billion to 9.8 billion, representing a growth of about 22.4% to 29.0% compared to the same period last year, when revenue was RMB 7.597 billion. The net loss attributable to the company's shareholders is expected to be in the range of RMB 100 million to RMB 50 million, a decrease of about 84.8% to 92.4% compared to the net loss attributable to the company's shareholders of RMB 658 million in the same period last year.
The Board of Directors believes that the main reasons for the changes in performance in this reporting period are: the continuous increase in the shipment volume of power and energy storage battery products, driving continuous revenue growth; cost reduction and efficiency improvement measures leading to a significant increase in gross profit; and effective cost control of expenses during the reporting period under the "cost reduction and efficiency improvement" strategy.
Related Articles

The essence of broker morning meeting | The dairy industry is expected to reach a turning point in supply and demand in 2026.

Oracle Corporation (ORCL.US) has reached a billion-dollar cloud service agreement with Skydance-Paramount (PARA.US).

CARSGEN-B(02171): The summary of the trial results of Soriatinib injection for adjuvant treatment of pancreatic cancer has been accepted for a poster presentation at the 2025 ESMO Annual Congress.
The essence of broker morning meeting | The dairy industry is expected to reach a turning point in supply and demand in 2026.

Oracle Corporation (ORCL.US) has reached a billion-dollar cloud service agreement with Skydance-Paramount (PARA.US).

CARSGEN-B(02171): The summary of the trial results of Soriatinib injection for adjuvant treatment of pancreatic cancer has been accepted for a poster presentation at the 2025 ESMO Annual Congress.

RECOMMEND

Total Investment of 1.2 Trillion Yuan: Yarlung Zangbo Hydropower Project Commences, Creating Investment Opportunities in Water Conservancy, Power Grid, and Cement Sectors
21/07/2025

Another Major Order Secured for Humanoid Robots, Setting a Global Record
21/07/2025

Seven Ministries Jointly Release 11 Measures to Encourage Foreign-Invested Enterprises to Reinvest in China
21/07/2025